First Look Analysts Research Calls for Tuesday, January 31
This report was sent to Briefing.com subscribers earlier today. Upgrades: > FibroGen (FGEN) upgraded to Outperform from Mkt Perform at William Blair > Inter & Co (INTR) upgraded to Buy from Neutral at Goldman; tgt lowered to $4.20 > LyondellBasell…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
This report was sent to Briefing.com subscribers earlier today.
Upgrades:
> FibroGen (FGEN) upgraded to Outperform from Mkt Perform at William Blair
> Inter & Co (INTR) upgraded to Buy from Neutral at Goldman; tgt lowered to $4.20
> LyondellBasell (LYB) upgraded to Overweight from Neutral at Atlantic Equities; tgt $110
> New Fortress Energy (NFE) upgraded to Buy from Neutral at BTIG Research; tgt $50
> Societe Television Francaise 1 (TVFCF) upgraded to Equal Weight from Underweight at Barclays
> WPP plc (WPP) upgraded to Overweight from Equal Weight at Barclays
Downgrades:
> Bank of America (BAC) downgraded to Neutral from Overweight at Atlantic Equities; tgt $40
> Eastern Bankshares (EBC) downgraded to Underweight from Neutral at JP Morgan; tgt lowered to $15
> Invitae (NVTA) downgraded to Sell from Neutral at Goldman; tgt $2
> iStar (STAR) downgraded to Mkt Perform from Outperform at Raymond James
> Nu Skin (NUS) downgraded to Hold from Buy at Jefferies; tgt lowered to $39
> Q2 Holdings (QTWO) downgraded to Neutral from Outperform at Robert W. Baird; tgt $32
> RELX (RELX) downgraded to Equal Weight from Overweight at Barclays
> Ubisoft (UBSFY) downgraded to Underperform from Buy at Jefferies
Others:
> Incyte (INCY) initiated with an Overweight at Piper Sandler; tgt $100
> Kura Oncology (KURA) initiated with a Buy at Stifel; tgt $25
Contact [email protected] for any questions or corrections.